• Policy
• Nicergoline for dementia listed at 50% of the highest-priced
• by Lee, Tak-Sun Sep 2, 2024 05:48am

• Policy
• Lily's orphan drug 'Jaypirca' receives conditional approval
• by Lee, Hye-Kyung Aug 30, 2024 05:50am

• Policy
• Reimb standards set for biliary tract cancer drug Pemazyre
• by Lee, Tak-Sun Aug 30, 2024 05:50am

• Company
• API competition↑ with entry of Chinese and Indian pharmas
• by Son, Hyung-Min Aug 30, 2024 05:50am

• Company
• Anti-cancer drug trends changes from IV→SC
• by Moon, sung-ho Aug 30, 2024 05:50am

• Company
• K-bio jumps into developing new drugs for pancreatic cancer
• by Son, Hyung-Min Aug 30, 2024 05:50am

• Policy
• Prices of Dukarb, Rosuzet cut 3 yrs through PVA
• by Lee, Tak-Sun Aug 30, 2024 05:49am

• Opinion
• [Reporter's View] pros and cons of concurrent reimb listing
• by Eo, Yun-Ho Aug 30, 2024 05:49am

• Company
• Korean pharma and biotechs expand R&D investments
• by Chon, Seung-Hyun Aug 29, 2024 04:32am

• Company
• Breast cancer drug Trodelvy receives DREC deliberations
• by Eo, Yun-Ho Aug 29, 2024 04:31am